JTC Employer Solutions Trustee Ltd Purchases 1,328,217 Shares of Haleon PLC Sponsored ADR $HLN

JTC Employer Solutions Trustee Ltd boosted its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 470.2% during the 1st quarter, HoldingsChannel.com reports. The fund owned 1,610,721 shares of the company’s stock after buying an additional 1,328,217 shares during the quarter. Haleon accounts for 1.3% of JTC Employer Solutions Trustee Ltd’s investment portfolio, making the stock its 10th biggest holding. JTC Employer Solutions Trustee Ltd’s holdings in Haleon were worth $16,115,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in HLN. Altshuler Shaham Ltd grew its position in shares of Haleon by 96.4% in the 1st quarter. Altshuler Shaham Ltd now owns 196,378 shares of the company’s stock valued at $1,966,000 after acquiring an additional 96,378 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Haleon by 64.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 57,526 shares of the company’s stock valued at $576,000 after purchasing an additional 22,508 shares during the period. Royal Bank of Canada lifted its stake in Haleon by 8.5% in the 1st quarter. Royal Bank of Canada now owns 3,063,916 shares of the company’s stock valued at $30,671,000 after purchasing an additional 238,841 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Haleon by 11.8% in the 1st quarter. Quantinno Capital Management LP now owns 1,221,499 shares of the company’s stock valued at $12,227,000 after purchasing an additional 128,917 shares during the last quarter. Finally, Public Employees Retirement System of Ohio grew its holdings in Haleon by 136.4% during the first quarter. Public Employees Retirement System of Ohio now owns 222,708 shares of the company’s stock worth $2,229,000 after purchasing an additional 128,493 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Tuesday, June 30th. Rothschild & Co Redburn downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Zacks Research lowered Haleon from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Haleon Stock Down 0.4%

Haleon stock opened at $10.23 on Thursday. The stock has a market cap of $45.04 billion, a P/E ratio of 26.22, a P/E/G ratio of 2.37 and a beta of 0.13. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a twelve month low of $8.65 and a twelve month high of $11.28. The company’s 50-day moving average price is $9.41 and its two-hundred day moving average price is $9.85.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.